Please login to the form below
Ultibro Breezhaler
This page shows the latest Ultibro Breezhaler news and features for those working in and with pharma, biotech and healthcare.
Novartis signs 'connected inhaler' deal with Propeller Health
Novartis and Propeller will connect the Breezhaler devices to Propeller's digital platform via a new custom sensor will passively record and transmit treatment compliance data. ... The inhaler is currently used as part of Novartis' Ultibro Breezhaler,
Latest news
-
Vectura to merge with SkyePharma in £441m deal
Vectura recorded revenues of £26m in the six-month period ended September 2015 - up 35% - as royalties increased on products such as Novartis' Ultibro Breezhaler (indacaterol/glycopyrronium bromide).
-
Novartis sets sights on connected inhaler
The next-generation Breezhaler falls within the pharma firm's collaboration with Qualcomm, whose Qualcomm Life subsidiary provides wireless solutions for the management of chronic diseases and sharing of medical information. ... Novartis plans a 2019
-
Novartis' combo COPD inhaler cleared in EU
Becomes first dual action bronchodilator approved in EU for COPD. Novartis' Ultibro Breezhaler has become the first dual action bronchodilator to be approved in the EU for chronic obstructive pulmonary disease ... Many COPD patients will now have a
-
Boehringer’s first cancer drug leads EMA recommendations
Novartis COPD inhaler recommended in EU. Elsewhere among the CHMP's recommendations, Novartis received backing for the Ultibro Breezhaler as a once-daily maintenance treatment to relive symptoms in adults with ... The product, which is to be marketed as
Vectura to merge with SkyePharma in £441m deal
Novartis sets sights on connected inhaler
Novartis' combo COPD inhaler cleared in EU
Boehringer’s first cancer drug leads EMA recommendations
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
CEO, Head of Health, UK
-
Six figure salary
- Valneva COVID-19 vaccine more effective than AZ
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s COVID-19 antiviral under review in Europe by EMA
- AZ’s Imfinzi boosts survival in biliary tract cancer
- MAKING THE FIRST YEAR MATTER
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Award-winning health agency 90TEN launches in the US
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
